The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.
Texas Instruments
TXN · a US exchange · USD · Market cap $270.4B · 33,000 employees
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers in the United States, China, the rest of Asia, Europe, the Middle East, Africa, Japan, and internationally.
FAIL · Does not pass the screenPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 10:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price285.75 USD at the 19 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 19 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans slightly to calls (put/call 0.72)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $218.86 to $251.69, base estimate $218.86 (screen dated 2026-11-19).
- Trend Markup
- Insiders insiders sold, $1,882,515, latest filing 2026-10-29
- Positioning political selling, disclosed 2026-10-14
- Options put/call open interest 0.72, read 2026-11-18
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Texas Instruments holds its Markup at $285.75. Elevated stress, defensive posture warranted, held for 11 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 11 days |
| Price at the screen | $285.75 |
| Valuation | 38.36 trailing · 25.57 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 1.39 |
Five Screens: TXN's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 40.62% | Below 33% | Fail |
| Interest-bearing cash | 4.79% | Below 33% | Pass |
| Receivables | 15.00% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Texas Instruments's business is in a permissible area, but its interest-bearing debt is about 41% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TXN's ethical verdict changes
Today TXN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 19 Nov 2026: it trades above our $218.86 fair value estimate, strong competitive moat, 27.70% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. The price runs 30.6% above the base estimate.
Third-party analyst targets: 29 covering, consensus Buy. The average target sits +19% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $218.86, with a range of $218.86 to $251.69, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain WordsTexas Instruments: Failing the Ethical Gauge in a Cyclical Storm
Imagine electronics designers worldwide racing to create the next gadget, and Texas Instruments is their go-to for semiconductors. The company operates in a highly cyclical industry, experiencing robust revenue growth of 23%, with a profit margin of 31% and a robust return on equity rating of 35%, highlighting its strong competitive moat. However, the market's optimism has the stock priced at a substantial 19% premium over our fair value estimate, which is a red flag in a cyclical industry.
The cyclical nature of the semiconductor industry poses a special risk. Currently, the company's valuation is high, which is typically a warning sign rather than a bargain, especially during peak earnings periods in such industries. A low multiple following a period of high earnings could indicate a cyclical value trap.
Unfortunately, despite its strong financial performance, Texas Instruments fails our ethical screen due to a concerning debt ratio. This is a critical factor in our evaluation process, as sustainable practices are as important as financial success. The consensus rating from analysts is a 'buy' with a median target price of $340, yet it's essential to consider not just the potential returns but the ethical standards of an investment.
Analysis, not advice.
| Forward P/E | 25.6xfairly priced for its growth rate |
| Trailing P/E | 38.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 7.71 |
| EPS, forward | 11.56 |
| Revenue growth | +27.7%strong top-line growth |
| Profit margin | 34.3%highly profitable on every dollar of sales |
| Return on equity | 39.7%an exceptional return on shareholder capital |
| FCF yield | 1.77% |
| Dividend yield | 1.84% |
| Debt to equity | 0.71moderate, manageable leverage |
| Current ratio | 5.60comfortably covers its short-term bills |
| Beta | 1.39moves a little more than the market |
| Short interest, float | 0.02% |
| 52-week range | 152.73 - 334.03 |
| Moat | STRONG |
| Market cap | $270.4B |
| Employees | 33,000 |
TXN-specific watchpoints · The things to watch: it already moves more than the market on an average day.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Top AI Stocks to Add to Your Portfolio for Healthy Returns Yahoo Finance · 17h ago
- What Have Lattice Stock Holders Had To Sit Through? Yahoo Finance · 17h ago
- 4 Tech Dividend Stocks Yielding Over 2% That Retirees Can Own for Growth and Income Yahoo Finance · 19h ago
- Is Texas Instruments' Sales Boom Its Biggest Risk? Yahoo Finance · 20h ago
- Global Wired Interface Market Report 2026: Size, Share, Trends, and Forecast to 2030 | Capitalize on High-Speed, Fiber Optic Demand with Intel, Broadcom, Qualcomm, and Infineon Yahoo Finance · 20h ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-29 | Kirk Ronald | Dir | S - Sale+OE | 6,065 | $1,882,515 |
| 2026-10-27 | Clark Janet F | Dir | S - Sale+OE | 4,306 | $1,302,404 |
| 2026-10-27 | Patsley Pamela H | Dir | S - Sale+OE | 4,532 | $1,366,670 |
| 2026-10-27 | Sanchez Robert E | Dir | S - Sale+OE | 6,065 | $1,832,923 |
| 2026-05-14 | BAHAI AHMAD | Officer | 5,000 | $1,545,636 | |
| 2026-05-14 | LIZARDI RAFAEL R | Chief Financial Officer | 47,734 | $14,706,996 | |
| 2026-05-14 | BAHAI AHMAD | Officer | 5,000 | $550,750 | |
| 2026-05-14 | LIZARDI RAFAEL R | Chief Financial Officer | 47,734 | $8,344,381 | |
| 2026-05-13 | COX CARRIE SMITH | Director | 8,838 | $2,708,029 | |
| 2026-05-13 | COX CARRIE SMITH | Director | 8,838 | $947,492 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-14 | Kevin Hern | Republican | sell | 15K–50K |
| 2026-10-14 | Kevin Hern | Republican | sell | 15K–50K |
| 2026-10-14 | Kevin Hern | Republican | sell | 15K–50K |
| 2026-10-13 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-07 | Ro Khanna | Democrat | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $297.76 | -5.3% | · | $947 | -5.3% |
| 2 months | $213.64 | +32.0% | $1.42 | $1,327 | +32.7% |
| 3 months | $189.09 | +49.1% | $1.42 | $1,499 | +49.9% |
| 6 months | $179.58 | +57.0% | $2.84 | $1,586 | +58.6% |
| 1 year | $196.77 | +43.3% | $5.62 | $1,462 | +46.2% |
| 2 years | $186.75 | +51.0% | $11.00 | $1,569 | +56.9% |
| 3 years | $156.26 | +80.5% | $16.14 | $1,908 | +90.8% |
| 5 years | $163.68 | +72.3% | $25.48 | $1,879 | +87.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TXN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.